Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study.
Inno A, Veccia A, D'Argento E, Morgillo F, Pizzutilo EG, Vitiello F, Pavan A, Lombardo F, Russano M, Sforza V, Colamartini F, Genova C, Chiari R, Cristofano A, Delconte A, Vattemi E, Dessi A, Galanti D, Busato S, Palazzolo G, Savastano C, Bianco A, Verderame F, Mazzi C, Marchetti F, Kinspergher S, Occhipinti D, Corte CMD, Piscazzi D, Gilli M, Bria E, Caffo O, Gori S.
Inno A, et al. Among authors: cristofano a.
Cancer Immunol Immunother. 2025 Jul 12;74(8):266. doi: 10.1007/s00262-025-04125-w.
Cancer Immunol Immunother. 2025.
PMID: 40650694